Table 2.

Surgical, radioactive iodine, radiotherapy, and systemic treatment characteristics.

	All patients  (N=28)
Surgery
No	8 (28.6%)
Yes	20 (71.4%)
Number of surgeries per patient
0	8 (28.6%)
1	14 (50.0%)
2	4 (14.3%)
4	2 (7.1%)
Type(s) of surgery
Lobectomy	7 (25.0%)
Thyroidectomy	12 (42.9%)
Lymph node dissection	9 (32.1%)
Metastasectomy	1 (3.6%)
Radioactive iodine
No	24 (85.7%)
Yes, after ATC diagnosis	2 (7.1%)
Yes, before ATC diagnosis	2 (7.1%)
EBRT to any site
No	7 (25.0%)
Yes	21 (75.0%)
EBRT to thyroid bed/neck
No	9 (32.1%)
Yes	19 (67.9%)
Total radiation dose (cGy)
< 4,000	11 (39.3%)
≥ 4,000	6 (21.4%)
Unknown	4 (14.3%)
Radiation fractionation (fractions/day)
1	8 (28.6%)
> 1	9 (32.1%)
Unknown	4 (14.3%)
More than one EBRT treatment course
No	19 (67.9%)
Yes	9 (32.1%)
EBRT initial intent
No EBRT	7 (25.0%)
Palliative	14 (50.0%)
Curative	7 (25.0%)
EBRT initial technique
No EBRT	7 (25.0%)
2D	4 (14.3%)
3D	3 (10.7%)
IMRT/VMAT	12 (42.9%)
Unknown	2 (7.1%)
Systemic therapy
No	14 (50.0%)
Yes	14 (50.0%)
Type(s) of chemotherapy used with EBRT
Doxorubicin	4 (14.3%)
Doxorubicin, Cisplatin	2 (7.1%)
Doxorubicin, Carboplatin, Paclitaxel	1 (3.6%)
Doxorubicin, Carboplatin, Paclitaxel, Cisplatin, Pemetrexed, Bevacizumab	1 (3.6%)
Doxorubicin, Carboplatin, Paclitaxel, Cyclophosphamide, Vinorelbine, Gemcitabine	1 (3.6%)
Carboplatin, Paclitaxel	1 (3.6%)
Sorafenib	1 (3.6%)
All treatments
Surgery + EBRT + Chemotherapy	10 (35.7%)
Surgery + EBRT	5 (17.9%)
EBRT + Chemotherapy	3 (10.7%)
EBRT only	3 (10.7%)
Surgery only	5 (17.9%)
Chemotherapy only	1 (3.6%)
No treatment	1 (3.6%)

Counts and column percentages are presented unless otherwise specified.

EBRT = external beam radiation therapy; IMRT = intensity modulated radiation therapy; VMAT = volumetric modulated arc therapy.